The ProMetic Life Sciences Inc. (PLI) Trading 5.1% Higher

The ProMetic Life Sciences Inc. (PLI) Trading 5.1% Higher

ProMetic Life Sciences Inc. (TSE:PLI) shares traded up 5.1% on Friday . The stock traded as high as C$1.72 and last traded at C$1.64. 2,755,761 shares traded hands during trading, an increase of 181% from the average session volume of 980,021 shares. The stock had previously closed at C$1.56.

Several research analysts recently weighed in on the company. National Bank Financial boosted their target price on ProMetic Life Sciences from C$2.00 to C$2.50 in a research note on Wednesday, August 30th. Royal Bank Of Canada dropped their target price on ProMetic Life Sciences from C$4.00 to C$3.50 and set an “outperform” rating on the stock in a research note on Wednesday, August 16th. TD Securities dropped their target price on ProMetic Life Sciences from C$4.50 to C$3.50 and set a “speculative buy” rating on the stock in a research note on Wednesday, August 16th. Scotiabank dropped their target price on ProMetic Life Sciences from C$4.75 to C$4.00 and set an “outperform” rating on the stock in a research note on Friday, July 7th. Finally, Canaccord Genuity dropped their target price on ProMetic Life Sciences from C$4.75 to C$4.50 and set a “buy” rating on the stock in a research note on Monday, June 19th. Two equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus target price of C$3.60.

The firm’s market cap is $1.16 billion. The firm has a 50-day moving average of $1.49 and a 200 day moving average of $1.76.

In other news, insider Bruce Pritchard bought 48,400 shares of the business’s stock in a transaction dated Tuesday, August 22nd. The shares were acquired at an average price of C$1.30 per share, for a total transaction of C$62,920.00. Also, Director Pierre Laurin sold 41,427 shares of ProMetic Life Sciences stock in a transaction dated Thursday, September 7th. The stock was sold at an average price of C$1.45, for a total value of C$60,069.15. Over the last 90 days, insiders acquired 174,150 shares of company stock worth $215,329 and sold 388,397 shares worth $507,577.

ProMetic Life Sciences Company Profile

Prometic Life Sciences Inc (ProMetic) is a Canada-based biopharmaceutical company. The Company has two segments: Small Molecule Therapeutics and Protein Technology. The Company offers its technology platform for large-scale drug purification of biologics, drug development, proteomics and the elimination of pathogens to various industries, and uses its own affinity technology that provides for extraction and purification of therapeutic proteins from human plasma in order to develop therapeutics and orphan drugs.

Related posts

Leave a Comment